| 000 | 01063 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250515041958.0 | ||
| 264 | 0 | _c20061128 | |
| 008 | 200611s 0 0 eng d | ||
| 022 | _a1744-7682 | ||
| 024 | 7 |
_a10.1517/14712598.6.10.1041 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLewiecki, E Michael | |
| 245 | 0 | 0 |
_aRANK ligand inhibition with denosumab for the management of osteoporosis. _h[electronic resource] |
| 260 |
_bExpert opinion on biological therapy _cOct 2006 |
||
| 300 |
_a1041-50 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 | _aDenosumab |
| 650 | 0 | 4 | _aDisease Management |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aOsteoporosis _ximmunology |
| 650 | 0 | 4 |
_aRANK Ligand _xantagonists & inhibitors |
| 773 | 0 |
_tExpert opinion on biological therapy _gvol. 6 _gno. 10 _gp. 1041-50 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1517/14712598.6.10.1041 _zAvailable from publisher's website |
| 999 |
_c16568209 _d16568209 |
||